Home button for the R&D Pipeline
Candidate button by product type
Candidates by sub-disease button

NEGLECTED DISEASE PRODUCT PIPELINE CANDIDATES BY DISEASE

TILE_DISEASE_maralia_OL_RGB
TILE_DISEASE_TB_OL_RGB
HIV_OL_RGB
TILE_DISEASE_kinetoplastids_OL_RGB
TILE_DISEASE_Diarrhoeal Diseases_OL_RGB
Helminth Infections
hip C
Salmonella Infections
BPM
dengue
Trachoma
Buruli Ulcer_OL_RGB2
TILE_DISEASE_Leprosy_OL_RGB
Leptospirosis
Rheumatic Fever
Cryptococcal Meningitis

Neglected diseases

This page presents in-depth, candidate-level information on the R&D product pipeline for neglected diseases as at October 2015.

The pipeline information on this page is presented per disease, and is sorted in descending order by number of products per category.

For diseases such as the kinetoplastid infections that are in fact a family of related sub-diseases, clicking on the hyperlinked text for these sub-diseases (e.g. sleeping sickness) will take you to a separate page with pipeline information specific to that disease.

Navigation

Select the hyperlinked disease and product tiles to go directly to the relevant section of the pipeline.

To return to the top of the page, simply click on the floating ‘Back to top’ icon in the bottom right-hand corner of your browser window.

If you would like to return to the overview page at any time, there is a link provided at the top of the page.

Malaria

124
products in the pipeline
Malaria drugs
Malaria vaccine_OL_RGB
Malaria diagnostics_OL_RGB
Malaria vectorcontrol_OL_RGB
Drugs
(45 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Artemether spray; ArTiMist Eastland Medical Systems Ltd
HC Berlin Pharma AG
ProtoPharma Limited
Dihydroartemisinin/Piperaquine (DHA-PQP) Paediatric Sigma Tau Group
Medicines for Malaria Venture (MMV)
Intra-rectal Artesunate WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Medicines for Malaria Venture (MMV)
Pyramax Paediatric (Pyronaridine/Artesunate) Medicines for Malaria Venture (MMV)
Shin Poong Pharmaceuticals
Tafenoquine GSK
Medicines for Malaria Venture (MMV)
Walter Reed Army Institute of Research (WRAIR)
DSM265 Medicines for Malaria Venture (MMV)
University of Texas Southwestern Medical Center
University of Washington
Monash University
Takeda Pharmaceutical Co
US National Institutes of Health (NIH)
Ferroquine (SSR97193) Sanofi
Fosmidomycin/Piperaquine Jomaa Pharma GmbH
GNF156 (KAF156) Genomics Institute of the Novartis Research Foundation
Medicines for Malaria Venture (MMV)
Novartis
NITD 609 (KAE 609; Cipargamin) Medicines for Malaria Venture (MMV)
Novartis Institute for Tropical Diseases
OZ439/Ferroquine (FQ) Medicines for Malaria Venture (MMV)
Sanofi
OZ439/Piperaquine; PQP Medicines for Malaria Venture (MMV)
Sanofi
ACT451840 Actelion Pharmaceuticals
Aminopyrdinel; MMV390048; MMV048 University of Cape Town
Swiss Tropical and Public Health Institute
Monash University
Medicines for Malaria Venture (MMV)
The Technology Innovation Agency, South Africa
CDRI 97/78 Central Drug Research Institute, India
Ipca Laboratories Ltd
SJ733 St. Jude Children’s Research Hospital
Rutgers University
University of California, San Francisco
Medicines for Malaria Venture (MMV)
Eisai Co Ltd
CDRI 99/411 Central Drug Research Institute, India
Ipca Laboratories Ltd
DDD498 University of Dundee
Medicines for Malaria Venture (MMV)
Merck Serono
GSK030 GSK
Medicines for Malaria Venture (MMV)
Histone deacetylase (HDAC) inhibitor; LMK235 Heinrich Heine University
Eskitis Institute for Drug Discovery
University of California, San Diego
Eberhard Karls Universität, Tübingen
JPC-2997 Army Malaria Institute, Australia
University of Miami
Jacobus Pharmaceutical Company
MMV253 AstraZeneca
Medicines for Malaria Venture (MMV)
NPC1161B University of Mississippi
P218 Medicines for Malaria Venture (MMV)
National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand
Monash University
Liverpool School of Tropical Medicine (LSTM)
Pyrazoles 21A092; PA21A092 Drexel University
University of Washington
Medicines for Malaria Venture (MMV)
Quinolones; ELQ-300; P4Q-391; Pro-drug ELQ-337 University of South Florida
Oregon Health and Science University
Drexel University
Monash University
Medicines for Malaria Venture (MMV)
Liverpool School of Tropical Medicine, (LSTM)
St. Jude Children’s Research Hospital
Reversed chloroquine molecules (RCQ) DesignMedix Inc
Portland State University
Acridones DesignMedix Inc
Portland State University
ACT213615 Actelion Pharmaceuticals
Amino-alcohols Merck Serono
Medicines for Malaria Venture (MMV)
Aminopyridines University of Cape Town
Swiss Tropical and Public Health Institute
Monash University
Medicines for Malaria Venture (MMV)
DHODH inhibitors (analogues of DSM265) University of Texas Southwestern Medical Center
University of Washington
Medicines for Malaria Venture (MMV)
Monash University
Diversity oriented synthesis (DOS) library lead (ML238) Broad Institute
DPAP inhibitors (ML4118S) Stanford University
University of California, Berkeley
dUTPase inhibitors University of York
University of Dundee
Medvir
GSK 3 Projects GSK
Medicines for Malaria Venture (MMV)
Novartis series lead optimization (imidazopyrazines) Genomics Institute of the Novartis Research Foundation
Swiss Tropical and Public Health Institute
Biomedical Primate Research Centre
Medicines for Malaria Venture (MMV)
Open Source Drug Discovery (OSM Series 4) University of Sydney
Medicines for Malaria Venture (MMV)
Oxaboroles (AN3661) Anacor Pharmaceuticals Inc
Medicines for Malaria Venture (MMV)
University of California, San Francisco
GSK
Pf NDH2 inhibitors (SL-2-64 CK-2-68 CK-2-25) Liverpool School of Tropical Medicine (LSTM)
University of Liverpool
Pf NMT inhibitors Imperial College of London
UK  MRC National Institute for Medical Research
University of Nottingham
University of York
Pfizer Inc
Protein Kinase inhibitors Monash University
Medicines for Malaria Venture (MMV)
Sanofi orthologue leads Sanofi
Medicines for Malaria Venture (MMV)
St. Jude/Rutgers Antimalarials  (Dihydropyridines) St. Jude Children’s Research Hospital
Rutgers University
University of South Florida
St. Jude/Rutgers Antimalarials (Diaminonaphthoquinones) St. Jude Children’s Research Hospital
Rutgers University
University of South Florida
Vaccines
(39 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
RTS,S/AS01E

GSK

PATH MVI

ChAd63/MVA ME-TRAP

University of Oxford

European Vaccine Initiative (EVI)

UK Medical Research Council The Gambia

Kenyan Medical Research Institute

Universite Cheikh Anta Diop Senegal

Centre National de Recherche et de Formation sur le Paludisme (CNRFP)

GMZ2 field/Alhydrogel

Statens Serum Institute

Navrongo Health Research Centre

Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso)

London School of Hygiene and Tropical Medicine (LSHTM)

Makerere University Kampala (MUK)

Medical Research Council (The Gambia)

European Vaccine Initiative (EVI)

MSP3-LSP/AlOH

African Malaria Network Trust (AMANET)

European Vaccine Initiative (EVI)

Institut Pasteur

University of Bamako

Centre National de Recherche et de Formation sur le Paludisme (CNRFP)

National Institute for Medical Research (NIMR – Tanga Centre)

ChAd63 AMA1/MVA AMA1

Southampton University Hospital

University College London

University of Oxford

Okairos/ReiThera

European Vaccine Initiative (EVI)

ChAd63 MSP1/MVA MSP1

Southampton University Hospital

University College London

University of Oxford

Okairos/ReiThera

European Vaccine Initiative (EVI)

ChAd63 RH5 +/- MVA RH5

University of Oxford

European Vaccine Initiative (EVI)

Okairos/ReiThera

GSK

Novartis

ChAd63/MVA PvDBP

University of Oxford

Okairos/ReiThera

International Centre for Genetic Engineering and Biotechnology (ICGEB)

CSVAC

University of Oxford

European Vaccine Initiative (EVI)

Royal College of Surgeons in Ireland (RCSI)

P27A/GLA-SE or Alhydrogel

European Vaccine Initiative (EVI)

University of Lausanne

Centre Hospitalier Universitaire Vaudois (CHUV)

Ifakara Health Institute, Tanzania

PfAMA1-DiCo/GLA-SE or Alhydrogel

Inserm

European Vaccine Initiative (EVI)

Biomedical Primate Research Centre BPRC (The Netherlands)

CIC BT505 Cochin Pasteur

Centre National de Recherche et de Formation sur le Paludisme

PfCelTOS FMP012/GLA-SE

Walter Reed Army Institute of Research (WRAIR)

GSK

PfPEBS-LSP/AlOH

Vac4All

Institut Pasteur

Sentinext Therapeutics

European Vaccine Initiative (EVI)

Centre Hospitalier Universitaire Vaudois (F.Spertini)

Pfs230D1M-EPA/Alhydrogel + Pfs25M-EPA/Alhydrogel National Institute of Allergy and Infectious Diseases (NIAID)
Pfs25-VLP/Alhydrogel

Fraunhofer CMB

Accelovance

PATH MVI

PfSPZ vaccine

Sanaria Inc

US Naval Medical Research Center (NMRC)

National Institute of Allergy and Infectious Diseases (NIAID)

University of Maryland Baltimore

Ifakara Health Institute Tanzania

Swiss Tropical and Public Health Institute (STPHI)

PATH MVI

PlasProtecT Griffith University
SE36/AlOH

Research Foundation for Microbial Diseases of Osaka University

Centre National de Recherche et de Formation sur le Paludisme

European Vaccine Initiative (EVI)

adjuv R21 (RTSS-derived) alone + with MeTRAP combined

University of Oxford

GSK

Okairos/ReiThera

European Vaccine Initiative (EVI)

Novartis

AnAPN-1

Johns Hopkins University Medical School

PATH MVI

EBA175/Rh5 combination vaccine National Institute of Allergy and Infectious Diseases (NIAID)
JAIVAC-2 Vaccine (PfMSP-Fu24+ PfF2) formulated with adjuvant

Malaria Vaccine Development Program (MVDP)

International Centre for Genetic Engineering and Biotechnology (ICGEB)

Zydus Cadila

MSP1 full length

University of Heidelberg

University Hospital Heidelberg

European Vaccine Initiative (EVI)

DNA/HuAd5 or ChAd63 (encoding CS AMA1 or ME-TRAP ) in prime-boost regimen

PATH MVI

US Naval Medical Research Center (NMRC)

University of Oxford

GenVec Inc

GSK

NMRC-M3V-Ad-PfCA in Adjuvant (7DW8-5)

US Naval Medical Research Cente (NMRC)

Aaron Diamond AIDS Research Center

GenVec Inc

Rockefeller University

Pfs 48/45

Radboud University Nijmegen

London School of Hygiene and Tropical Medicine (LSHTM)

Gennova Biopharmaceuticals

Kilimanjaro Christian Medical College (KCMC)

Statens Serum Institut

PRIMVAC (PRIMALVAC)

European Vaccine Initiative (EVI)

Inserm

PvDBPII

PATH MVI

International Centre for Genetic Engineering and Biotechnology (ICGEB)

Malaria Vaccine Development Program (MVDP)

Syngene International Limited

Recombinant P. falciparum CSP-based vaccine adjuvanted with GLA-SE

National Institute of Allergy and Infectious Diseases (NIAID)

Pfenex Inc

Infectious Disease Research Institute (IDRI)

Johns Hopkins Malaria Research Institute

University of Maryland Baltimore

Recombinant P. vivax CSP-based Vaccine

Protein Potential LLC

National Institute of Allergy and Infectious Diseases (NIAID)

RH5 (InnoMalVac)

University of Oxford

EXPRES2ION BIOTECHNOLOGIES

European Vaccine Initiative (EVI)

PAMVAC (PAMCPH/PlacMalVac)

University of Copenhagen

European Vaccine Initiative (EVI)

EXPRES2ION BIOTECHNOLOGIES

CMC Biologics A/S

University of Abomey-Calavi

l’Institut de Recherche pour le Développement (IRD)

Eberhard Karls Universität, Tübingen

VMP002 – second generation E. coli expressed P. vivax CSP-based vaccine Walter Reed Army Institute of Research (WRAIR)
Recombinant P. falciparum CSP

Walter Reed Army Institute of Research (WRAIR)

Imperial College London

Infectious Disease Research Institute (IDRI)

3M Drug Delivery Systems

SAPN nanoparticle P. falciparum CSP

Walter Reed Army Institute of Research (WRAIR)

US  Department of Defence (DOD)

Alpha-O Peptides AG

Pfs25-IMX313

University of Oxford

European Vaccine Initiative (EVI)

Okairos/ReiThera

GSK

Imaxio

CSP RI conjugates

PATH MVI

New York University (NYU)

Merck MSD

EBA-Rh

PATH MVI

Walter and Elizabeth Hall Institute (WEHI)

Gennova

PvDBP3-5

PATH MVI

Walter and Elizabeth Hall Institute (WEHI)

Diagnostics
(28 candidates)
Product/Candidate name Key developers/partners Early development Late development
2DPN (2-D paper network) University of Washington
NanoMal malaria assay (Q-POC)

NanoMal Consortium (QuantuMDx)

St. George’s University

The Karolinska Insititute

Tubingen University

Nucleic acid lateral flow immunoassays (NALFIA) – DIAGMAL Consortium

Koninklijk Instituut voor de Tropen (KIT)

Forsite Diagnostics Ltd

Q-Bioanalytic GmbH

Global Innovation Network Oy

Parasight (2nd generation) Sight Diagnostics Ltd
Rapid Assessment of Malaria (RAM) Device

Disease Diagnostic Group LLC

Case Western Reserve University

Urine Malaria Test

Johns Hopkins University

Fyodor BioTechnologies

A better tool to identify P. vivax infections/P. vivax serology

Foundation for Innovative New Diagnostics (FIND)

Walter & Eliza Hall Institute

Fundaçao do Medican Tropical

PNG Institute of Medical Research

Ehime University

Queensland Institute of Medical Research

University of Melbourne

P. falciparum infection detection test (Improved highly sensitive RDTs for P falciparum)

Foundation for Innovative New Diagnostics (FIND)

Centers for Disease Control and Prevention (CDC)

Hospital for Tropical Diseases in London (UK)

Institut Pasteur du Cambodge (Cambodia)

Microcoat GmbH (Germany)

PATH (USA)

Queensland Institute for Medical Research/AMI (Australia)

Université Cheikh Anta Diop  (Senegal)

Universidad Peruana Cayetano Heredia (Peru)

ZeptoMetrix (USA)

ADCIA 2120 hematology system Siemens
Amplino Scout Amplino BV
Cell-phone based microscopy Boston University
CellScope (cell phone plus microscope)

CellScope

University of California Berkeley

Computer-assisted slide reading Hydas World Health
DIAMETER infection detection test PATH
Electric impedance microflow cytometry

Massachusetts Institute of Technology

Carnegie Mellon University

Foldscope

Stanford University

University of California Berkeley

G6PD deficiency diagnostic

PATH

GSK

High throughput LAMP

Eiken Chemical

Foundation for Innovative New Diagnostics (FIND)

Hospital for Tropical Diseases

Kelch13 blood test Mahidol-Oxford Tropical Medicine Research Unit
LUCAS

Holomic LLC

University of California Los Angeles

Malaria Pf/Pv Detect InBios International Inc
Microfluidic modeling University of Washington
Paper microfluidic cartridge with acridine orange staining

Intellectual Ventures Lab

University of Washington

Ring-stage survival assay (RSA)

Institut Pasteur du Cambodia

US National Institutes of Health (NIH)

Single nucleotide polymorphism (SNP) genotyping Broad Institute
Spectraphone QuantaSpec Inc
SpectraWave and SpectraNet Claro Scientific LLC
VCS technology

Beckman Coulter

University College Hospital

Vector Control Products
(12 candidates)
Product/Candidate name Key developers/partners Early development Late development
Olyset Duo (a bi-treated net based on permethrin and pyriproxyfen) Sumitomo Chemical
Innovative Vector Control Consortium (IVCC)
A novel bed net with synergist and IRS formulation. London School of Hygiene and Tropical Medicine (LSHTM)
Chlorfenapyr-based IRS formulation BASF
Innovative Vector Control Consortium (IVCC)
LLIN combination 1 BASF
Innovative Vector Control Consortium (IVCC)
MCD Project In2Care
Biogents AG
CTF200
Ifakara Health Institute, Tanzania
Penn State University
Bayer Discovery Platform
(IVCC new active ingredient 1)
Innovative Vector Control Consortium (IVCC)
Bayer AG
Sumitomo Active ingredient library screening
(IVCC new active ingredient 2)
Innovative Vector Control Consortium (IVCC)
Sumitomo Chemical
Syngenta Active ingredient library screening
(IVCC new active ingredient 3)
Innovative Vector Control Consortium (IVCC)
Syngenta
Crop protection development compound Innovative Vector Control Consortium (IVCC)
Agircultural AI review Innovative Vector Control Consortium (IVCC)
LLIN combination 2 Innovative Vector Control Consortium (IVCC)
LLIRS formulation Innovative Vector Control Consortium (IVCC)

Tuberculosis

117
products in the pipeline
TB drugs_OL_RGB
TB diagnostics_OL_RGB
TB vaccine_OL_RGB
Drugs
(51 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
PaMZ (PA-824/ Moxifloxacin/ Pyrazinamide) TB Alliance
AZD5847

National Institute of Allergy and Infectious Diseases (NIAID)

AstraZeneca

PNU-100480 (Sutezolid) Sequella Inc
SQ-109

National Institute of Allergy and Infectious Diseases (NIAID)

Sequella Inc

CB2009 Canopus BioPharma Inc
CB3900 Canopus BioPharma Inc
TBA-354 (nitroimidazole) TB Alliance
BDM-I BioDiem Ltd
CPZEN45

Microbial Chemistry Research Foundation

National Institute of Allergy and Infectious Diseases (NIAID)

Eli Lilly and Company

Infectious Disease Research Institute (IDRI)

YourEncore

PBTZ 169

Innovative Medicines for Tuberculosis (iM4TB)

EPFL:École polytechnique fédérale de Lausanne

Q203 Qurient Therapeutics
SQ-609

National Institute of Allergy and Infectious Diseases (NIAID)

Sequella Inc

SQ-641 (capuramycin)

National Institute of Allergy and Infectious Diseases (NIAID)

Sequella Inc

TBI-166 Institute of Materia Medica
Unnamed Okairos TB drug Okairos AG
SND-159

University of Medicine and Dentistry of New Jersey

Snowdon Inc

ATP Synthase Inhibitors

TB Alliance

California Institute for Biomedical Research

Azaindoles TB Alliance
Bacterial PPMO (RNA-based Therapeutic Candidates for XDR-TB)

Karolinska Institute

Sarepta Therapeutics (formerly AVI BioPharma)

Bismuth-thiols Microbion Corporation
Cyclopeptides

Sanofi

TB Alliance

DF-152 Dafra Pharma International
Diarylquinolines

University of Auckland

Janssen

TB Alliance

Energy metabolism inhibitors

University of Pennsylvania

TB Alliance

EsxA secretion inhibitors (BBH7 and BTP15)

More Medicines for TB Consortium (MM4TB): EPFL Global Health Institute

University of Cologne

Vichem Chemie Research Ltd

Semmelweis University

Ethionamide enhancer molecules Bioversys AG
Fungal (actinomycete) metabolites

Mycosnthetix Inc

University of Illinois at Chicago

Hesed 1000 Ensoltek Co Ltd
Indazoles

GSK

TB Alliance

InhA Inhibitors

GSK

TB Alliance

Inhibitors of isoprenoid biosynthesis

Infectious Disease Research Institute (IDRI)

Colorado State University

Eli Lilly and Company

LeuRS inhibitors

GSK

Anacor Pharmaceuticals

Macrolides

TB Alliance

Sanofi

Malate synthase inhibitors Texas A&M University
Menaquinone biosynthesis inhibitors Eli Lilly and Company
MmpL3 inhibitors TB Alliance
POA Prodrugs

Yonsei University

TB Alliance

Radezolid Rib-X Pharmaceuticals
RNA polymerase inhibitors

Rutgers University

TB Alliance

SCAR – Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis FAPESP SÂO PAULO RESEARCH FOUNDATION
Spectinamides

St Jude Children’s Research Hospital

University of Tennessee Health Science Center

Colorado State University

University of Zurich

Microbiotix Inc

SPR-113 International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi
Thiophene Carboxamides

Calibr Calafornia Institute for Biomedical Research

TB Alliance

TL1 Inhibitors Sequella Inc
Tryptanthrins

Korea Research Institute of Chemical Technology

Yonsei University

Unnamed Achillion TB drug Achillion Pharmaceuticals Inc
Unnamed Anacor TB drug (1) Anacor Pharmaceuticals
Unnamed Anacor TB drug (2) Anacor Pharmaceuticals
Unnamed Fit Biotech Oyj TB drug Fit Biotech Oyj
Unnamed Medisyn TB drug Medisyn Technologies Inc
Ureas

TB Alliance

Sanofi

Diagnostics
(42 candidates)
Product/Candidate name Key developers/partners Early development Late development
AV Breath Test Avisa Pharma Inc
CellScope (cell phone plus microscope)

Makerere University

University of California Berkeley

University of California San Francisco

World Health Partners

C-Tb-TST Statens Serum Institut
Fluorobot

ConsultASK Ltd

ASK-M

Ateknea Solutions

Genedrive

Xcelris Labs Ltd

Epistem

HYDRA-1K InSilixa
InterGam Rapid Immuno Suspension Assay (IRISA-TB) Antrum Biotech
LATE PCR with Lights on/Lights Off Probes and PrimeSafe technology

Stellenbosch University South Africa

Brandeis University

Hain Lifescience Gmbh

MBio multiplexed immunoasssay platform

MBio Diagnostics Inc

Foundation for Innovative New Diagnostics (FIND)

TAM-TB Assay

University of Munich

Swiss Tropical and Public Health Institute

NIMR-Mbeya Medical Research Center (MMRC)

TBDx system

Keck Graduate Institute

Claremont BioSolutions LLC

University of Washington

PATH

Seattle & King County TB Clinic

Leardon Solutions

Ustar Biotechnologies

Urinary antigen detection (LAM)

Tuberculosis Clinical Diagnostics Research Consortium

Alere

Foundation for Innovative New Diagnostics (FIND)

Loop-mediated isothermal amplification (LAMP) of DNA (TB)

Eiken Chemical

Foundation for Innovative New Diagnostics (FIND)

Aeonose The eNose Compnay
Xpert Ultra and Xtend XDR

Cepheid

Rutgers University

Alere Q TB assay Alere
BreathLink Menssana Research INC
DiagCORE STAT-Diagnostica
Enigma ML Enigma Diagnostics
EOSCAPE-TB and TB-DST Wave 80 biosciences
Prototype breathanalyzer Next Dimensions
Q-POC (Q-TB) MTBC and MDR assays QuantuMDx
Savanna RT-PCR Testing Platform

Northwestern Global Health Foundation

Quidel Corporation

Antibody detection test (1st generation)

Antigen Discovery Inc

Natural and Medical Sciences Institute (NMI) Tübingen

MBio Diagnostics Inc

University of Medicine and Dentistry of New Jersey (UMDNJ)

MicroMol Gmbh

Foundation for Innovative New Diagnostics (FIND)

Automated slide reader Becton Dickinson (BD)
BD MAX Becton Dickinson (BD)
Beta Lactamase Detection (GBD TB REaD POC – Enzymatic detection M. tuberculosis β-lactamase reporter assay)

Global BioDiagnostics

Stanford University

Texas A&M University

Foundation for Innovative New Diagnostics (FIND)

B-SMART assay Sequella Inc
DigiportX TB MVIP + Software Consulting Gmbh

GenePOC real-time PCR assays for MTBC and resistance genotyping

(RIF/INH and FLQ)

GenePOC Inc
Handheld poin-of-care diagnostic device McMaster University
Immiprint system ProteinLogic
Immunochromatographic strip test

TB Biosciences

New York University

Lonestar Owlstone
Magnetic barcode assay Massachusetts General Hospital
Novel antigen panel for lateral flow test Infectious Disease Research Institute (IDRI)
Novel reagents for serological diagnosis of tuberculosis Burnet Institute
Rapid colorimetric drug susceptibility test (MDR-XDRTB Colour Test)

London School of Hygiene and Tropical Medicine

Foundation for Innovative New Diagnostics (FIND)

RDT to detect LAM Boston University
Real-time polymerase amplification MTBC assays

TwistDx

London School of Hygiene and Tropical Medicine

PATH

SOMAmer-based tuberculosis (TB) biomarker assay SomaLogic Inc
Unyvero Curetis AG
Vaccines
(24 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Crucell Ad35/AERAS-402

Aeras

Crucell

H1-IC31

Statens Serum Institut

Intercell AG

H4/AERAS-404 + IC31

Aeras

Sanofi Pasteur

Statens Serum Institut

Intercell AG

H56/ AERAS-456 + IC31

Aeras

Statens Serum Institut

Intercell AG

M72 + AS01E

Aeras

GSK

MVA85A / AERAS-485

Aeras

University of Oxford

Emergent BioSolutions

RUTI Archivel Farma SL
VPM1002

TuBerculosis Vaccine Initiative

Stellenbosch University, South Africa

Children’s Infectious Disease Clinical Research Unit

Vakzine Projekt Management GmbH

Ad5Ag85A McMaster University
Dar-901

Aeras

Dartmouth-Hitchcock Medical Center

H1-CAF01 Statens Serum Institut
ID93 in GLA-SE

Aeras

Infectious Disease Research Institute (IDRI)

IMX-TB2

University of Oxford

Imaxio

MTBVAC01

TuBerculosis Vaccine Initiative (TBVI)

University of Zaragoza Spain

BIOFABRI

Ag85A DNA or ESAT6/Ag85A chimeric DNA vaccines Shanghai H&G Biotechnology Co Ltd
BCGIP Medicine in Need
Carbohydrate-protein conjugate vaccines Karolinska Institute
Live attenuated Mtb derivatives (AECM) Albert Einstein College of Medicine
TB-SLP

Transgene SA

ISA Pharmaceuticals BV

THSTI/UD TB Vaccine

Translational Health Science Technology Institute, India

University of Delhi, South Campus

HspC with TB antigens ImmunoBiology Ltd
IKEPLUS Albert Einstein College of Medicine
Live attenuated Mtb derivatives (Pasteur)

Institut Pasteur

French National Institute of Health and Medical Research (Inserm)

National Center for Scientific Research (CNRS)

rBCG and T&B epitopes

University of Science, Malaysia

Finlay Institute, Cuba

hiv

82
products in the pipeline
HIV vaccine_OL_RGB
HIV drugs_OL_RGB
HIV diagnostics_OL_RGB
Vaccines
(45 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III

Ad35-GRIN; MVA.HIV-consv

pSG2.HIVconsv-DNA

University of Oxford

International AIDS Vaccine Initiative (IAVI)

ALVAC (vCP2438) + C gp120/MF59

(HVTN 100)

Sanofi

Novartis

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

GTU-MultiHIV B DNA LIPO-5

French Institute of Health and Medical Research (Inserm)

French National Agency for AIDS Research (ANRS)

HIVIS 03 DNA (TaMoVac)

Karolinska Institute

Muhimbili University of Health and Allied Sciences Tanzania

Swedish International Development Cooperation Agency

Walter Reed Army Institute of Research (WRAIR)

LIPO-5

French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Sanofi-Aventis

MVA.HIVA

IDT Biologika

University of Oxford

UK Medical Research Council (UK MRC)

University of Nairobi

Kenya AIDS Vaccine Initiative

MVA-CMDR Walter Reed Army Institute of Research  (WRAIR)
pDNA + rTV + MHRP gp145

Chinese Center for Disease Control and Prevention

US MilitaryHIV Research Program (MHRP)

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

Vacc-4x

Bionor Pharma ASA

Celgene Corporation

AAV-PG9

International AIDS Vaccine Initiative (IAVI)

National Institute of Allergy and Infectious Diseases (NIAID)

Children’s Hospital of Philadelphia

Ad4-mgag + Ad4-EnvC150 + AIDSVAX B/E

(HVTN 110)

PaxVax Inc

Global Solutions for Infectious Diseases (GSID)

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

ALVAC-HIV (vCP1521) + gp120 B/E (AIDSVAX B/E) + C gp120/MF59

(HVTN 097)

Global Solutions for Infectious Diseases (GSID)

IDT

Novartis

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Disease (NIAID)

CH505 Sequential Env: EnvSeq T/F EnvSeq 53 EnvSeq 78EnvSeq 100

Duke University

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

Clade C gp140 utilizing Chimp Ad 6 and Chimp Ad 7 vectors

HIV Vaccine Trials Network (HVTN)

US Military HIV Research Program (MHRP)

National Institute of Allergy and Infectious Diseases (NIAID)

CN54gp140 (study name: X001)

International AIDS Vaccine Initiative (IAVI)

Imperial College London

DNA [5 Env (clade A B AE C and D) + 1 Gag; CON-S gp120]  +  gp120 Env protein (clades A B AE C) adjuvanted with GLA

Infectious Disease Research Institute (IDRI)

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

EN41-FPA2 (gp4-based vaccine)

Sanofi Pasteur

University of Granada

Polymun Scientific

University of Surrey

PX’Therapeutics

GTU-MultiHIV

Imperial College of London School of Medicine

UK Medical Research Council (UK MRC)

HIV-MAGpDNA + GENEVAX IL-12 pDNA + VSVgag+VSVenvC

(HVTN 112)

Profectus Biosciences

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

MHRP gp145

Chinese Center for Disease Control and Prevention

US Military HIV Research Program (MHRP)

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

MVA mosaic

(IPCAVD006/CrucellA002)

Crucell (Janssen)

Ragon Institute

National Institute of Allergy and Infectious Diseases (NIAID)

MVA/HIV62 National Institute of Allergy and Infectious Diseases (NIAID)

MVA62B + gp120 B/E (AIDSVAX B/E)

(HVTN 114)

GeoVax

Global Solutions For Infectious Diseases (GSID)

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

MVA-CMDR  + DNA Nat-B env [HV13288] or DNA CON-S env [HV13287 or DNA Mosaic env [trivalent HV13284 HV13285 and HV13286]

(HVTN 106)

Duke University

US Military HIV Research Program (MHRP)

National Institute of Allergy and Infectious Diseases (NIAID)

p24CE1/2 DNA and p55Gag DNA plus GENEVAX IL-12 DNA Plasmid

University of Washington Seattle

National Cancer Institute (NCI)

Ichor Medical Systems Inc

Althea

Profectus BioSciences Inc

National Institute of Allergy and Infectious Diseases (NIAID)

PENNVAX-G

Inovio Pharmaceuticals Inc

National Institute of Allergy and Infectious Diseases (NIAID)

US Military HIV Research Program (MHRP)

PENNVAX-GP IL-12 DNA

(HVTN 098)

Inovio Pharmaceuticals Inc

National Institute of Allergy and Infectious Diseases (NIAID)

US National Institutes of Health (NIH)

Polyvalent DNA Protein HIV Vaccine (PDPHV): Env (A B C E)/Gag (C)-expressing DNA plasmids and recombinant gp120 (A B C E) protein + GLA adjuvant

University of Massachussets Medical School

Infectious Disease Research Institute (IDRI)

Waisman Biomanufacturing

National Institute of Allergy and Infectious Diseases (NIAID)

SeV-G(NP) (also referred to as Sendai)

International AIDS Vaccine Initiative (IAVI)

ID Pharma Co Ltd (formerly called DNAVEC Corporation)

Project San Francisco (PSF) Kigali

Kenyatta National Hospital-KAVI

St Stephen’s Centre London

Tiantian vaccinia HIV vaccine

Chinese Center for Disease Control and Prevention

National Vaccine and Serum Institute China

Trimeric gp 140 protein + Alum

(IPCAVD008/CrucellA003)

Crucell (Janssen)

Beth Israel Deaconess Medical Center  Massachusetts (BIDMC)

US MilitaryHIV Research Program (MHRP)

National Institute of Allergy and Infectious Diseases (NIAID)

VICHREPOL

Federal Medical and Biological Agency Russia

Ministry of Education and Science Russian Federation

Moscow Institute of Immunology

Ad26mosaic + MVAmosaic + C gp140/alum

9IPCAVD009/CrucellA004)

Crucell (Janssen)

Beth Israel Deaconess Medical Center (BIDMC)

US Military HIV Research Program (MHRP)

International AIDS Vaccine Initiative (IAVI)

National Institute of Allergy and Infectious Diseases (NIAID)

ALVAC (vCP2438) + C gp120/MF59 or C gp120/alum

(HVTN 107)

Sanofi

Novartis

Infectious Disease Research Institute (IDRI)

Bill & Melinda Gates Foundation

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

ALVAC (vCP2438) + C gp120/MF59 or C gp120/AS01B

(HVTN 113)

Sanofi

Novartis

GSK

Bill & Melinda Gates Foundation

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

DNA PT123 + C gp120/MF59 or C gp120/AS01B

(HVTN 108)

Novartis

GSK

IPPOX

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

DNA PT123 + NYVAC PT1/PT4 + C gp120/MF59 or C gp120/AS01B

(HVTN 109)

Sanofi

IPPOX Foundation

Novartis

GSK

Bill & Melinda Gates Foundation

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

NYVAC PT1/PT4 + C gp120/MF59 or C gp120/AS01B

(HVTN 109)

Sanofi

EuroVacc

Novartis

GSK

Bill & Melinda Gates Foundation

HIV Vaccine Trials Network (HVTN)

National Institute of Allergy and Infectious Diseases (NIAID)

Vacc-C5

Bionor Pharma ASA

University of Maryland

Ab Discovery/Immunobiology International AIDS Vaccine Initiative (IAVI)
b121a and b122a

Indian Institute of Science

Jawaharlal Nehru Centre for Advanced Scientific Research

International AIDS Vaccine Initiative (IAVI)

Duke University

BG505 International AIDS Vaccine Initiative (IAVI)
CDV International AIDS Vaccine Initiative (IAVI)
iVSV International AIDS Vaccine Initiative (IAVI)
VSV International AIDS Vaccine Initiative (IAVI)
Drugs
(19 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
LPV/r pellets with dual NRTI FDC

Drugs for Neglected Diseases initiative (DNDi)

Cipla Ltd

UNITAID

National Department of Health, South Africa

University of Nairobi

KEMRI Walter Reed Project

Dapivirine ring

International Partnership for Microbicides (IPM)

Janssen Sciences Ireland UC (previously Tibotec)

Long-acting injectable formulation of rilpivirine (TMC278) as PrEP

PATH

Janssen

HIV Vaccine Trials Network (HVTN)

NIH

Two ‘4-in-1′ LPV/r-based Fixed-Dose Combinations Drugs for Neglected Diseases initiative (DNDi)
Dapivirine gel

International Partnership for Microbicides (IPM)

Janssen Sciences Ireland UC (previously Tibotec)

Tenofovir gel

CONRAD

Centre for the AIDS Programme of Research in South Africa

US Agency for International Development (USAID)

VivaGel

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health & Human Development

Star Pharma

Amphora

National Institute of Allergy and Infectious Diseases (NIAID)

EvoFem

Dapivirine film

International Partnership for Microbicides (IPM)

Janssen Sciences Ireland UC (previously Tibotec)

Dapivirine-darunavir gel

International Partnership for Microbicides (IPM)

Janssen Sciences Ireland UC (previously Tibotec)

Maraviroc ring and dapivirine-maraviroc ring

International Partnership for Microbicides (IPM)

ViiV healthcare

Maraviroc vaginal and rectal gels

International Partnership for Microbicides (IPM)

ViiV healthcare

MZC/PC-1005 Gel (MIV-150 + zinc acetate + carrageenan) Population Council
Dapivirine rectal gel

International Partnership for Microbicides (IPM)

Janssen Sciences Ireland UC (previously Tibotec)

DS001 (L167) DS004 (L872) DS005 (L882)

International Partnership for Microbicides (IPM)

Merck MSD

DS003 (BMS793) vaginal tablet and vaginal ring

International Partnership for Microbicides (IPM)

BMS

DS007 (L-644 peptide)

International Partnership for Microbicides (IPM)

Merck MSD

MIV-150 + Zinc + vaginal ring Population Council
Tenofovir and tenofovir/emtricitabine vaginal Tablets CONRAD
Diagnostics
(18 candidates)
Product/Candidate name Key developers/partners Early development Late development
Liat Analyzer (COBAS Liat System) Iquum Roche Molecular Diagnostics
LYNX HIV p24 antigen assay Northwestern Global Health Foundation
Quidel Corporation
Mbio CD4 system Mbio Inc
Merck Millipore Muse Auto CD4/C4% system Merck MSD
Mobile microfluidic immunoassay (mChip) ColumbiaUniversity
Amsterdam University Medical Center
Opko Diagnostics
Rwanda-Zambia HIV Research Group
PanNAT Platform (Qualitative HIV assay) Micronics Inc
POC rapid RT-PCR testing platform (NWGHF Savanna Viral Load Test and Platform) Northwestern Global Health Foundation (NWGHF)
Quidel Corporation
Visitect CD4/Burnet Institute CD4 Initiative Burnet Institute
Massachusetts General Hospital
Partners AIDS Research Center
Omega Diagnostics
FlashOne (A rapid portable HIV detection and monitoring system for resource limited settings) Thermal Gradient
Rapid test for recent HIV infection Immunetics Inc
CD4+ T-lymphocyte test Imperial College of London School of Medicine
PATH
PortaScience
University of Washington
EOSCAPE-NAT HIV Rapid RNA Assay system WAVE 80 Biosciences
Genedrive Epistem Ltd
Gene-RADAR Platform Nanobiosym Diagnostics
Non-instrumented nucleic acid amplification (NINA) platform PATH
RT CPA HIV-1 Viral Load Test Ustar Biotechnologies
University of Victoria
Truelab Real Time micro PCR System Molbio Diagnostics (Tulip Group-Bigtec laboratories partnership)
Viral load assay using BART (Bioluminesent Assay in Real-Time) technology Lumora Ltd
44
products in the pipeline
Kinetoplastids vaccine_OL_RGB

Vaccines

Kinetoplastids drugs_OL_RGB

Drugs

Kinetoplastids diagnostics_OL_RGB

Diagnostics

kinetoplastids vectorcontrol_OL_RGB

Vector Control Products

Vaccines
(18 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
LEISH-F1 Infectious Disease Research Institute (IDRI)
LEISH-F2 Infectious Disease Research Institute (IDRI)
LEISH-F3 Infectious Disease Research Institute (IDRI)
Gennova Biopharmaceuticals
ASP-2 Kyushu University
Cruzipain National Administration of Laboratories and Institutes of Health (ANLIS)
Ministry of Health of Argentina
GP82 Universidade Federal de São Paulo
Live attenuated Trypanisoma cruzi Instituto de Patología Experimental-CONICET
Universidad Nacional de Salta Argentina
Live Trypanosoma rangeli Servicio Nacional de Chagas Córdoba Argentina
MASP University of Texas at El Paso
Tc24 Sabin Vaccine Institute
Tc52 Universidad de Buenos Aires
Helmholtz Centre for Infection Research, Germany
TcG1 Sabin Vaccine Institute
University of Texas Medical Branch
TcG2 Sabin Vaccine Institute
University of Texas Medical Branch
TcG4 Sabin Vaccine Institute
University of Texas Medical Branch
TcVac2 University of Texas Medical Branch
TSA-1 Sabin Vaccine Institute
LdNH36 with Lutzomyia sandfly antigens Sabin Vaccine Institute
LeishDNAvax Charité – Universitätsmedizin Berlin
Drugs for Neglected Diseases initiative (DNDi)
Indian Institute of Chemical Biology
Institut Pasteur de Tunis
London School of Hygiene and Tropical Medicine (LSHTM)
MOLOGEN AG
Rajendra Memorial Research Institute of Medical Sciences, India
The Hebrew University of Jerusalem
Drugs
(12 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Fexinidazole

Drugs for Neglected Diseases initiative (DNDi)

HAT Platform Partners

Sanofi-Aventis

Swiss Tropical and Public Health Institute

E1224/benznidazole (combination treatment)

Drugs for Neglected Diseases initiative (DNDi)

Eisai

Anfoleish

Drugs for Neglected Diseases initiative (DNDi)

PECET (Program for the Study and Control of Tropical Diseases), Universidad de Antioquia Medellin Colombia

Humax Pharmaceutical, Colombia

Oxaborole SCYX-7158

Drugs for Neglected Diseases initiative (DNDi)

Anacor Pharmaceuticals Inc

Pace University

SCYNEXIS Inc

Swiss Tropical and Public Health Institute

Advinus Therapeutics

DB829 (CPD-0802)

Consortium for Parasitic Drug Development

Georgia State University

The University of North Carolina at Chapel Hill

Corifungin

Acea Biotech

Sandler Centre for Drug Discovery (UCSF)

CpG-D35

Drugs for Neglected Diseases initiative (DNDi)

University of Osaka

VL-2098

Drugs for Neglected Diseases initiative (DNDi)

TB Alliance

Advinus Therapeutics

Endolytics

Nitroimidazole

Drugs for Neglected Diseases initiative (DNDi)

University of Auckland

TB Alliance

Monash University

Epichem

Murdoch University

Federal University of Ouro Preto (UFOP) Brazil

Institut Pasteur Korea (IPK) South Korea

Oxachagas

Drugs for Neglected Diseases initiative (DNDi)

Anacor Pharmaceuticals Inc

SCYNEXIS Inc

Murdoch University

Wuxi AppTech

Sandexis

Laboratory of Microbiology Parasitology and Hygiene (LMPH), University of Antwerp

Nitroimidazole backup (VL)

Drugs for Neglected Diseases initiative (DNDi)

TB Alliance

Auckland University

Laboratory of Microbiology Parasitology and Hygiene (LMPH) University of Antwerp

WuXi AppTech

Oxaleish programme  (primary lead: DNDi/Oxa-2035804)

Drugs for Neglected Diseases initiative (DNDi)

Anacor Pharmaceuticals

SCYNEXIS Inc

Diagnostics
(12 candidates)
Product/Candidate name Key developers/partners Early development Late development
LAMP Test

Foundation for Innovative New Diagnostics (FIND)

Murdoch University

Obihiro University

Eiken Chemical Co Ltd

ELISA test for Leishmania antigens

Foundation for Innovative New Diagnostics (FIND)

Drugs for Neglected Diseases initiative (DNDi)

International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR,b)

Kenya Medical Research Institute (KEMRI)

LAMP Test

Foundation for Innovative New Diagnostics (FIND)

Royal Tropical Institute, Netherlands

Wellcome Trust

Sanger Institute

TiPharma

Eiken Chemical Co Ltd

Chunap (Chagas urine nanoparticle test) Johns Hopkins University
IDRI diagnostic next generation

Infectious Disease Research Institute (IDRI)

WHO Special Programme for Research and Training in Tropical Diseases

LAMP Test

Foundation for Innovative New Diagnostics (FIND)

INGEBI/CONICET

London School of Hygiene and Tropical Medicine

Pontificia Universidad Javeriana and Universidad de los Andes

Eiken Chemical Co

24-kDa fusion protein ELISA

Instituto Nacional de Laboratorios de Salud

Universitat de Barcelona

Universidade Federal de Goiás

University of Giessen

Electrochemical impedance spectroscopy

Oswaldo Cruz Foundation

Universidade Federal de Pernambuco

PATH Chagas Immunochromatographic Strip Test (ICS) PATH
Lateral-flow RDT (2nd generation) Foundation for Innovative New Diagnostics (FIND) Standard Diagnostics
DPP Leishmaniasis RDT

Infectious Disease Research Institute (IDRI)

Chembio Diagnostics Systems Inc.

QuantiFERON-Leishmania Banaras Hindu University
Vector Control Products
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
Genetic modification of a tsetse fly gut bacterium blocking parasite proteins Swansea University
Identification of different chemical blends to repel tsetse flies Université des Montagnes
31
products in the pipeline
Diarrhoeal Disvaccine_OL_RGB
Diarrhoeal disdrugs_OL_RGB
Diarrhoeal disdiagnostics_OL_RGB
Vaccines
(28 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
PXVX-0200 PaxVax Inc
BRV-PV Serum Institute of India
BRV-TV

ChengDu Institute of Biological Products Co Ltd (CDIBP)

Instituto Butantan São Paulo

Shantha Biotech

Chemically prepared glycoconjugate

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health & Human Development

Live attenuated Vibrio cholerae strain 638 (CV638) Finlay Institute
ACE527 (aroC omp F and Omp C-based live attenuated; may include dmLT adjuvant)

Johns Hopkins Bloomberg School of Public Health

PATH

Pierrel Research USA

TD Vaccines A/S

China National Biotec Group

Anti-adhesin based subunit vaccine

US Naval Medical Research Center (NMRC)

PATH

ETVAX

PATH

Scandinavian BioPharma

RV3_BB

PATH

Murdoch University

Australian Government

Bio-Farma

Gadjah Mada University

Otago University

Royal Children’s Hospital

University of Melbourne

WHO

VirG-based live attenuated (WRSS1 WRSs3 WRSf3) Walter Reed Army Institute of Research (WRAIR)
dmLT

National Institute of Allergy and Infectious Diseases (NIAID)

PATH

Tulane University

P2-VP8 recombinant subunit rotavirus

vaccine

PATH
GMMA GSK (ex-Novartis Vaccines Institute for Global Health)
GuaBA-based live attenuated (CVD1208S) University of Maryland (UMB) Baltimore
GVXN SD133 GlycoVaxyn
Inactivated trivalent Shigella whole cell PATH
Anti-adhesin-toxoid fusion (MEFA)

Kansas State University (KSU)

Johns Hopkins Bloomberg School of Public health (JHBSPH)

LT-ST fusion/LTB-ST conjugate

The International Enteric Vaccine Consortium (EntVac)

Global Health and Vaccination Research (GLOBVAC)

STOPENTERICS

PATH

Second-generation 1208S attenuated

Shigella vaccine expressing CF/CS

antigens and LT toxoid

Center for Vaccine Development, University of Maryland
Typhetec Prokarium
Heat stable Rotavirus Vaccine Hilleman Laboratories (Merck MSD and Wellcome Trust joint venture)
34kDa OMP National Institute of Cholera and Enteric Diseases, India
DB Fusion PATH
InvaplexAR Walter Reed Army Institute of Research (WRAIR)
OMV University of Navarra, Spain
PSSP1 International Vaccine Institute  (IVI)
Synthetic glycoconjugate Institut Pasteur
Ty21a typhoid vaccine expressing Shigella LPS Protein Potential
Drugs
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
AKT10081 Akthelia Pharmaceuticals
AKT10082 Akthelia Pharmaceuticals
Diagnostics
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Multiplex fluorescence optofluidic microscopy for diagnosis of enteric parasites California Institute of Technology
24
products in the pipeline
Hel Inf vaccine_OL_RGB
Hel Infdrugs_OL_RGB
Hel Infdiagnostics_OL_RGB
Vaccines
(15 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Bilhvax (Sh-GST28) Eurogentec
French National Institute of Health and Medical Research (Inserm)
Institut Pasteur
NaAPR-1 Sabin Vaccine Institute PDP
NaGST-1 Sabin Vaccine Institute PDP
Sm14 (Schisto) Brazillian Innovation Agency
Oswaldo Cruz Foundation
Sm28-GSTe Institute Pasteur
Sm28-TPIe Harvard School of Public Health
Sm97 paramyosin Cornell University
Case Western Reserve University
National Institute of Allergy and Infectious Diseases (NIAID)
SmTSP-2c (tetraspanin D) Sabin Vaccine Institute PDP
Ov-103 The Onchocerciasis Vaccine for Africa (TOVA) Initiative
Sabin Vaccine Institute PDP
Ov-RAL-2 The Onchocerciasis Vaccine for Africa (TOVA) Initiative
Sabin Vaccine Institute PDP
CT-SOD State University of New York
Oswaldo Cruz Foundation
Brown University
rSm-p80 Texas Tech University
Sm23 Johns Hopkins
Harvard University
Sm29 Oswaldo Cruz Foundation
The George Washington University
Sm-p80-VR1020 Texas Tech University
Drugs
(6 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Moxidectin Pfizer Inc.
WHO/TDR
Medicines Development for Global Health

Co-Arinate FDC (Artesunate-Sulfamethoxypyrazine/

Pyrimethamine)

Dafra Pharma Research & Development BVBA
Oxantel pamoate Swiss TPH
University of Basel
Deuterated praziquantel analogues CoNCERT Pharmaceuticals Inc
US National Institutes of Health (NIH)
Praziquantel paediatric Astellas Pharma
Merck Serano
Swiss TPH
TI Pharma
Emodepside Bayer AG
Drugs for Neglected Diseases initiative (DNDi)
Astellas Pharma
Diagnostics
(3 candidates)
Product/Candidate name Key developers/partners Early Development Late Development
Up-converting phosphore technology lateral flow assay (UCP-LF strop) Leiden University Medical Center
Ampath Laboratories
Filaria Detect IgG4 ELISA InBios
Ov16/Wb123 biplex rapid test PATH
US National Institutes of Health (NIH)
Standard Diagnostic (SD-Alere)

Hepatitis C

17
products in the pipeline
Hep c diagnostics_OL_RGB
Hep c vaccine_OL_RGB
Hep Cdrugs_OL_RGB

Diagnostics

Diagnostics
(10 candidates)
Product/Candidate name Key developers/partners Early development Late development
Alere Q  (HCV-RNA) Alere
ASSURED-chip: an accurate affordable and rapid microfluidics-based diagnosis of Hepatitis-C virus Biyani Girls College (BGC)
Genedrive (HCV qual) Epistem Ltd
Institut Pasteur
GeneXpert (HCV-RNA) Cepheid
HCV LAMP assay All India Institute of Medical Sciences
Islamic Azad University, Iran
PanNAT platform (Qualitative HCV assay) Micronics Inc
Truelab PCR (HCV-RNA) Molbio Diagnostics Pvt Ltd (A Tulip Group – Bigtec labs partnership)
POC microfluidic diagnostic system Daktari Diagnostics
EOSCAPE-HCV RNA Wave 80 biosciences
RT CPA (HCV-RNA) Ustar Biotechnologies
University of Victoria
Vaccines
(4 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Ad3ChNSmut1 / MVA-Nsmut in prime boost regimen National Institute of Allergy and Infectious Diseases (NIAID)
2nd generation ChAd3 Ii-NSmut / MVA Ii-Nsmut vaccine – prime boost (PEACHI consortium) GSK
University of Oxford
ReiThera
St James’ Hospital Dublin
Kantonsspital St Gallen
HCV-1 recombinant gpE1/gpE2 University of Alberta
Novartis
Delta3 Burnet Institute
Drugs
(3 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Asunaprevir Daclatasvir Ribavirin and Pegylated Interferon Alpha-2a Bristol-Myers Squibb
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Grazoprevir/Elbasvir Merck MSD
Next-Gen HCV Combination (ABT-493 ABT-530) AbbVie
13
products in the pipeline
Salmonella vaccine_OL_RGB
Vaccines
(13 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
O:2-TT + Vi-TT (Bivalent conjugate enteric fever vaccine) US National Institutes of Health (NIH)
Lanzhou Institute of Biological Products
Vi-CRM197 (conjugate typhoid vaccine) Novartis Vaccines Institute for Global Health
Biological E
WTO5 Microscience Ltd
CVD 1902 + CVD 909 (live oral bivalent enteric fever vaccine) University of Maryland Center for Vaccine Development
Bharat biotech
Vi-DT (conjugate typhoid vaccine) International Vaccine Institute  (IVI)
US National Institutes of Health (NIH)
PT BioFarma
Bivalent conjugate (O:45-CRM197
and O:9-CRM197)
Novartis Vaccines Institute for Global Health
COPS: FliC conjugates using CVD 1925 and CVD 1943 reagent strains University of Massachusetts Boston (UMB)
Bharat Biotech
Wellcome Trust
CVD 1931 and CVD 1944 (Bivalent live oral NTS vaccine) University of Maryland Center for Vaccine Development
NTS-GMMA GSK (ex-Novartis Vaccines Institute for Global Health)
O:4-TT US National Institutes of Health (NIH)
Lanzhou Institute of Biological Products Co Ltd
OmpD University of Birmingham
O:2-CRM197 + Vi-CRM197 (Bivalent conjugate enteric fever vaccine) Novartis Vaccines Institute for Global Health
Biological E
O:2-DT + Vi-DT (Bivalent conjugate enteric fever vaccine) International Vaccine Institute (IVI)

bacterial pneumonia and meningitis

12
products in the pipeline
BPMvaccine_OL_RGB
BPMdiagnostics_OL_RGB
Vaccines
(11 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
GSK2189242A PATH
GSK
MRC labs
London School of Hygiene and Tropical Medicine (LSHTM)
PhtD/pneumolysoid/PcpA common protein vaccine Sanofi Pasteur
Pneumococcal whole cell vaccine PATH
Boston Children’s Hospital
V114 Merck MSD
Serum Institute of India
Live Recombinant Attenuated Salmonella Vaccine Arizona State University
Trivalent protein Genocea Biosciences
Liverpool School of Tropical Medicine (LSTM)
Low-cost thermostable ACWXY meningococcal conjugate vaccine PATH
Serum Institute of India
PneuGEM Mucosis BV
Radboud University Nijmegen Medical Centre
Pneumococcal 13-valent conjugate vaccine SinoVac Biotech Ltd
Low-cost pneumococcal conjugate vaccine PATH
Serum Institute of India
Novel conjugation technology using common protein carriers Multiple Antigen Presenting System (MAPS) PATH
Affinivax Inc
Diagnostics
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Paper-based microfluidic POC device University of Texas at El Paso

dengue

5
products in the pipeline
Dengue drugs_OL_RGB
kinetoplastids vectorcontrol_OL_RGB
BPMdiagnostics_OL_RGB
Drugs
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
CB5300 Canopus BioPharma Inc
DengueCide NanoViricides Inc
Vector Control Products
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
RIDL-Sterile Insect Technique Oxitec Ltd
Wolbachia-infected mosquitoes Monash Univresity
Oswaldo Cruz Foundation (FIOCRUZ)
University of Melbourne
University of Wisconsin
James Cook University
University of California, Davis
Oxford University Clinical Research Unit, Vietnam
Diagnostics
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Liat dengue assay IQuum Inc

trachoma

4
products in the pipeline
Trachoma vaccine_OL_RGB
BPMdiagnostics_OL_RGB
Vaccines
(3 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
T cell vaccine based on dendritic cell immunoprotemics Pan-Provincial Vaccine Enterprise Inc (PREVENT)
University of British Columbia
British Columbia Centre for Disease Control
rMOMP vaccine National Institute of Allergy and Infectious Diseases (NIAID)
University of California, Irvine
Identification of new vaccine constructs against Chlamydia trachomatis Prokarium
Imperial College London
Diagnostics
(1 candidate)
Product/Candidate name Key developers/partners Early development Late development
Antibody assay for trachoma Centers for Disease Control and Prevention (CDC)

buruli ulcer

4
products in the pipeline
Hel Infdiagnostics_OL_RGB
Buruli ulcervaccine_OL_RGB
Diagnostics
(3 candidates)
Product/Candidate name Key developers/partners Early development Late development
LAMP) assay Foundation for Innovative New Diagnostics (FIND)
Noguchi Memorial Institute for Medical Research
Mycolactone detection by thin layer chromatography (TLC) Foundation for Innovative New Diagnostics (FIND)
WHO
Harvard University
Protein antigen capture assay Foundation for Innovative New Diagnostics (FIND)
Swiss Tropical and Public Health Institute
Standard Diagnostics (SD-Alere)
Vaccines
(1 candidate)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
TMX 201 adjuvant-based Buruli ulcer vaccine Swiss TPH
Telormedix SA

leprosy

3
products in the pipeline
Lepdiagnostics_OL_RGB
Lepdrugs_OL_RGB
Diagnostics
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
Leprosy next generation Infectious Disease Research Institute (IDRI)
OrangeLife
A test combining an antibody-based assay and a T-cell assay into one field test Leiden University Medical Center
Drug
(1 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
Bedaquiline Janssen-Cilag
Leonard Wood Memorial
Johnson & Johnson

leptospirosis

2
products in the pipeline
Lepdiagnostics_OL_RGB
Diagnostics
(2 candidates)
Product/Candidate name Key developers/partners Early development Late development
New Vertical Flow RDT for serodiagnosis of Leptospirosis Institut Pasteur
Complete DPP Test for Human Leptospirosis Chembio Diagnostics Systems Inc
Weill Medical College Cornell University
Oswaldo Cruz

rheumatic fever

2
products in the pipeline
RFvaccine_OL_RGB
Vaccines
(2 candidates)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
A vaccine for group A streptococcal
to prevent rheumatic heart disease
Institute for Glycomics, Griffith University
StreptInCor (vaccine candidate peptide) University of São Paulo

cryptococcal meningitis

1
product in the pipeline
Cryptodrugs_OL_RGB
Drugs
(1 candidate)
Product/Candidate name Key developers/partners Discovery

Pre-

clinical

Phase I Phase II Phase III
VT-1129 Viamet pharmaceuticals
NIH Therapeutics for Rare and Neglected Diseases programme

This is the first comprehensive global picture of the neglected disease R&D pipeline since 2012. It looks at 34 of the 35 neglected diseases within the scope of G-FINDER survey (Ebola is not included), covering all product categories including vector control products, and all stages of research from early stage R&D through to product registration. The data is the result of a comprehensive review of the neglected disease R&D landscape conducted by Policy Cures in late 2015, and is presented as a snapshot of the pipeline as at October 2015. For details on the methodology behind this review please see the home page; for a quick overview of the diseases and associated products covered in this pipeline refer to the G-FINDER R&D matrix.

Candidate button by product type
Candidates by sub-disease button
Policy Cures Research Logo, Brisbane Street, email info[at]policycuresresearch.org